基蛋生物科技股份有限公司 关于 2023 年第三季度业绩网上说明会 召开情况的公告 证券代码：603387 证券简称：基蛋生物 公告编号：2023-033 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 基蛋生物科技股份有限公司（以下简称"公司"）于2023年11月8日10:00- 11:00在上证所信息网络有限公司上证路演中心平台（以下简称"上证路演中心"） 采用网络互动方式召开"基蛋生物2023年第三季度业绩网上说明会"。关于本次 业绩说明会的召开事项，公司已于2023年10月28日在《上海证券报》及上海证券 交易所网站上披露了《基蛋生物科技股份有限公司关于召开2023年第三季度业绩 说明会的公告》（公告编号：2023-032）。现将有关事项公告如下： 一、本次说明会召开情况 2023年11月8日，公司董事长苏恩本先生、公司财务总监倪文先生、公司董 事会秘书刘葱女士、公司独立董事万遂人先生出席了本次业绩说明会。公司就 2023年第三季度报告、经营状况、产品等问题与投资者进行互动交流和沟通，在 信息披露允许的范围内就投资者普 ...

Financial Performance - Q3 2023 revenue was CNY 297,605,041.36, a decrease of 26.33% year-over-year[2] - Net profit attributable to shareholders was CNY 60,349,670.97, down 58.49% compared to the same period last year[2] - Basic earnings per share for Q3 2023 was CNY 0.12, reflecting a decline of 58.62% year-over-year[2] - In Q3 2023, the company reported a revenue of RMB 1.001 billion, a decrease of 27.32% compared to the same period last year[11] - The net profit attributable to shareholders was RMB 229 million, down 51.80% year-on-year, while the net profit excluding non-recurring items was RMB 198 million, a decrease of 56.84%[11] - Total operating revenue for the first three quarters of 2023 was CNY 1,000,961,989.28, a decrease of 27.3% compared to CNY 1,377,167,848.88 in the same period of 2022[19] - Net profit for the first three quarters of 2023 was CNY 233,662,791.59, a decline of 51.4% from CNY 481,071,216.93 in the same period of 2022[20] - The company reported a profit before tax of CNY 249,393,861.89 for the first three quarters of 2023, down 53.8% from CNY 539,806,744.44 in the same period of 2022[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,767,784,884.31, an increase of 2.46% from the end of the previous year[3] - As of September 30, 2023, total assets amounted to RMB 3.768 billion, compared to RMB 3.677 billion at the end of 2022[15] - Total liabilities as of the end of the third quarter of 2023 amounted to CNY 1,088,462,214.02, compared to CNY 1,012,840,595.85 at the end of the previous year[17] - Total equity as of the end of the third quarter of 2023 was CNY 2,679,322,670.29, an increase from CNY 2,664,597,352.39 at the end of the previous year[17] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 146,507,664.68, a decrease of 29.52%[2] - Operating cash flow for the first nine months of 2023 was CNY 146,507,664.68, a decrease of 29.4% compared to CNY 207,880,331.23 in the same period of 2022[25] - Cash inflow from operating activities totaled CNY 1,268,627,997.86, while cash outflow was CNY 1,122,120,333.18, resulting in a net cash flow from operating activities of CNY 146,507,664.68[25] - Cash and cash equivalents decreased to RMB 410.16 million from RMB 646.25 million at the end of 2022[14] - The total cash and cash equivalents at the end of the period was CNY 407,471,086.12, down from CNY 1,133,577,261.76 at the beginning of the period[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,255[8] - The largest shareholder, Su Enben, holds 39.77% of the shares, totaling 201,670,295 shares[8] Product and Market Performance - The company's self-produced product revenue reached RMB 766.21 million, an increase of 29.31% year-on-year, with the POCT (excluding COVID-19) segment generating RMB 531.05 million, up 14.83%[12] - The core product Getein1600 saw steady growth with over 660 units installed in the first three quarters of 2023, reinforcing the company's leading position in the POCT field[12] - The MAGICL6000 product line achieved nearly 800 units installed in Q3 2023, with a cumulative installation of nearly 1,700 units, contributing to a significant revenue increase of 156.48% in the chemiluminescence segment[12] - The company launched the self-developed Metis6000 fully automated immunoassay line in Q1 2023, with nearly 40 units installed by Q3, over 50% of which are in secondary hospitals or above[12] Cost Management and Future Plans - Total operating costs for the first three quarters of 2023 were CNY 779,963,522.08, down 8.0% from CNY 847,993,776.91 in the previous year[19] - Research and development expenses for the first three quarters of 2023 were CNY 160,651,078.79, an increase of 5.0% compared to CNY 151,894,491.01 in the previous year[19] - The company continues to focus on conventional business and market expansion while enhancing cost control and efficiency[12] - The company plans to continue focusing on market expansion and new product development in the upcoming quarters[18]

证券代码：603387 证券简称：基蛋生物 公告编号：2023-032 基蛋生物科技股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 11 月 08 日(星期三)上午 10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 11 月 01 日(星期三)至 11 月 07 日(星期二)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IR@getein.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 基蛋生物科技股份有限公司（以下简称"公司"）于 2023 年 10 月 28 日发布 公司 2023 年第三季度报告，为便于 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2023-031 基蛋生物科技股份有限公司 2023 年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.1 元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2023/9/26 | － | 2023/9/27 | 2023/9/27 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司 2023 年 9 月 13 日的 2023 年第一次临时股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本 507,153,517 股为基数，每股派发现金红利 0.1 元 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2023-030 基蛋生物科技股份有限公司 2023 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 27 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 227,478,832 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 44.8540 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，由公司董事长苏恩本主持。本次股东大会 采用现场投票和网络投票相结合的方式进行表决。会议的召集、召开、表决形式 (一) 股东大会召开的时间：2023 年 9 月 13 日 (二) 股东大会召开的地点：南京市六合区沿江工业开发区博富路 9 号基蛋生 物科技股份有限公司四楼会议室 (三) 出席会议的普通股股东 ...

上海市锦天城（南京）律师事务所 法律意见书 上海市锦天城（南京）律师事务所 关于基蛋生物科技股份有限公司 2023年第一次临时股东大会的 法律意见书 地址：南京市建邺区江东中路 347 号国金中心一期 27、28 楼 电话：025-68515000 传真：025-68516601 邮编：210019 上海市锦天城（南京）律师事务所 法律意见书 上海市锦天城（南京）律师事务所 1 上海市锦天城（南京）律师事务所 法律意见书 在本法律意见书中，本所律师仅对本次股东大会的召集、召开程序、出席会议 人员资格、召集人资格及会议表决程序、表决结果是否符合《公司法》《上市公司 股东大会规则》等法律、法规、规范性文件及《公司章程》的规定发表意见，不对 会议审议的议案内容以及这些议案所表述的事实或数据的真实性及准确性发表意见。 关于基蛋生物科技股份有限公司 2023年第一次临时股东大会的 法律意见书 致：基蛋生物科技股份有限公司 上海市锦天城（南京）律师事务所（以下简称"本所"）接受基蛋生物科技股 份有限公司（以下简称"公司"）委托，就公司召开2023年第一次临时股东大会（以 下简称"本次股东大会"）的有关事宜，根据《中华人民 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2023-029 基蛋生物科技股份有限公司 关于 2023 年半年度业绩网上说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 基蛋生物科技股份有限公司（以下简称"公司"）于2023年9月12日10:00- 11:00在上证所信息网络有限公司上证路演中心平台（以下简称"上证路演中心"） 采用网络互动方式召开"基蛋生物2023年半年度业绩网上说明会"。关于本次业 绩说明会的召开事项，公司已于2023年8月29日在《上海证券报》及上海证券交 易所网站上披露了《基蛋生物科技股份有限公司关于召开2023年半年度业绩说明 会的公告》（公告编号：2023-027）。现将有关事项公告如下： 一、本次说明会召开情况 2023年9月12日，公司董事长苏恩本先生、公司财务总监倪文先生、公司董 事会秘书刘葱女士、公司独立董事万遂人先生出席了本次业绩说明会。公司就 2023年半年度报告、经营状况、产品等问题与投资者进行互动交流和沟通，在信 息披露允许的范围内就投资者普遍关注的问题 ...

截至本公告披露日，基蛋生物科技股份有限公司（以下简称为"公司"） 控股股东苏恩本先生持有公司股份 201,670,295 股，占公司总股本的 39.77%。 本次质押解除后，苏恩本先生所持有的公司股份不存在质押的情形。 基蛋生物科技股份有限公司 关于控股股东股份质押解除的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603387 证券简称：基蛋生物 公告编号：2023-028 苏恩本先生和一致行动人（南京爱基商务信息咨询有限公司、苏恩奎先 生、王勇先生、孔婷婷女士）合计持有公司股份 224,399,330 股（均为无限售流 通股），占公司总股本的 44.25%。本次质押解除后，苏恩本先生和一致行动人所 持有的公司股份不存在质押的情形。 一、本次股份质押解除的基本情况 公司于近日接到控股股东苏恩本先生通知，获悉苏恩本先生将其质押给华泰 证券股份有限公司的 5,900,000 股无限售流通股全部解除质押。详情如下： 单位：股 | 股东名称 | 苏恩本 | | --- | --- | | ...

基蛋生物科技股份有限公司 2023 年第一次临时股东大会会议资料 基蛋生物科技股份有限公司 Getein Biotech,Inc. 2023 年第一次临时股东大会 会议资料 中国 南京 二零二三年九月 基蛋生物科技股份有限公司 2023 年第一次临时股东大会会议资料 基蛋生物科技股份有限公司 2023 年第一次临时股东大会会议资料目录 | 序号 | 会议资料名称 | | | --- | --- | --- | | 1 | 基蛋生物科技股份有限公司 2023 | 年第一次临时股东大会会议须知 | | 2 | 基蛋生物科技股份有限公司 2023 | 年第一次临时股东大会会议议程 | | 3 | 基蛋生物科技股份有限公司 2023 | 年第一次临时股东大会会议议案 | | 议案 | 1 关于公司 2023 年半年度利润分配预案的议案 | | 基蛋生物科技股份有限公司 2023 年第一次临时股东大会会议资料 基蛋生物科技股份有限公司 2023 年第一次临时股东大会 会议须知 为维护全体股东的合法权益，确保基蛋生物科技股份有限公司（以下简称"基 蛋生物"或"公司"）股东大会的正常秩序和议事效率，保证股东大会的顺利进行， ...

Financial Performance - In the first half of 2023, the company achieved a net profit of RMB 171,580,000.10, with a net profit attributable to shareholders of RMB 168,720,454.45[6]. - The distributable profit for the first half of 2023 was RMB 1,471,522,388.59, while the parent company's distributable profit was RMB 1,249,703,008.38[6]. - The proposed cash dividend distribution is RMB 1 per 10 shares, amounting to a total cash dividend of RMB 50,715,351.70, which represents 30.06% of the net profit attributable to shareholders[7]. - The company's operating revenue for the first half of 2023 was approximately ¥703.36 million, a decrease of 27.73% compared to ¥973.21 million in the same period last year[24]. - The net profit attributable to shareholders was approximately ¥168.72 million, down 48.84% from ¥329.80 million year-on-year[24]. - The basic earnings per share decreased by 49.23% to ¥0.33 from ¥0.65 in the previous year[25]. - The weighted average return on equity fell by 8.03 percentage points to 6.81% from 14.84% year-on-year[25]. - The net cash flow from operating activities was approximately ¥117.84 million, a decline of 15.47% compared to ¥139.40 million in the same period last year[24]. - The company's net assets attributable to shareholders increased slightly by 0.73% to approximately ¥2.50 billion from ¥2.48 billion at the end of the previous year[24]. Market Trends and Opportunities - The global in vitro diagnostics market is expected to exceed $127.4 billion in 2022, with significant growth in emerging markets like China and India[31]. - The domestic in vitro diagnostics market is projected to reach ¥160.3 billion in 2023, driven by aging population and increased healthcare demand[33]. - The immunodiagnostics market in China reached ¥27.95 billion in 2022 and is expected to grow to ¥30.86 billion in 2023[34]. - The low-flow immunodiagnostic market in China reached 6.8 billion in 2022, with steady growth over the past five years[36]. - The domestic POCT market size grew from 4.3 billion in 2015 to 11.2 billion in 2019, with a compound annual growth rate of 21.10%, and is expected to reach 29 billion by 2024[38]. - The heart marker POCT market in China is projected to grow significantly due to increasing cardiovascular disease prevalence, which affected 330 million patients in 2019[39]. Product Development and Innovation - The company registered 22 new reagent products in the first half of 2023, including 8 in the POCT field and 3 in the chemiluminescence field[45]. - The company has developed a diverse product system, transitioning from single POCT products to a range of technologies including chemiluminescence and biochemical detection[43]. - The company aims to expand its market presence from grassroots medical institutions to higher-tier hospitals and overseas markets[43]. - The company has established eight technical platforms, including POCT and chemiluminescence, to meet diverse clinical needs[43]. - The company launched several new products, including the Getein1600 with a throughput of 50 tests/hour and a storage capacity of 500,000 samples, and the CM800 with a throughput of 800 tests/hour[46]. - The Metis6000 immunoassay line can process 400 tests/hour with a first sample turnaround time of 12 minutes, showcasing high efficiency[47]. - The company is focusing on automation and high-throughput solutions to cater to the increasing demands of grassroots medical institutions[40]. - The company is developing a modular design for the SH2000 fully automated sample processing system, enhancing product configuration flexibility to meet diverse user needs[56]. Research and Development - The company invested 138 million yuan in R&D during the reporting period, an increase of 18.43% year-on-year, representing 19.56% of the total revenue[76]. - The company holds 519 valid patents, including 342 authorized patents, with 34 invention patents and 281 utility model patents[76]. - The company plans to increase investment in new product research and development, expanding its R&D team to meet the growing demands of the in vitro diagnostics industry[94]. - The company emphasizes the importance of protecting its core technologies through patents and confidentiality agreements to mitigate the risk of technology leakage[95]. - The company is aware of the risk of talent loss in its R&D team and is implementing competitive compensation and career development plans to retain key personnel[95]. Financial Management and Strategy - The company is transitioning to a Just-In-Time (JIT) procurement model to optimize supply chain management and reduce costs[53]. - The company has implemented a series of procurement management regulations to standardize and streamline the procurement process, ensuring quality and efficiency[53]. - The company has developed a comprehensive material control process, including new material development and supplier quality management[54]. - The company aims to enhance customer loyalty and market barriers through direct sales to key clients, such as hospitals and private groups[52]. - The company is focusing on enhancing its capital reserves and improving its financial stability through strategic financing activities[158]. Environmental Responsibility - The company has committed to environmental protection policies and has not faced any administrative penalties related to environmental issues during the reporting period[101]. - The wastewater generated by the company meets the Class 3 standards of the Comprehensive Wastewater Discharge Standard (GB8979-1996) after pretreatment[102]. - The company has implemented measures to ensure that noise levels at the factory boundary comply with the Class 2 standards of the Industrial Enterprise Boundary Environmental Noise Emission Standards (GB12348-2008)[105]. - The company has established a hazardous waste storage facility that complies with relevant regulations and has signed disposal agreements with qualified hazardous waste disposal agencies[106]. - The company’s production processes generate minimal organic waste gases, which are treated with activated carbon adsorption devices before being released[108]. Shareholder and Corporate Governance - The company has not reported any changes in its board of directors, supervisors, or senior management during the reporting period[100]. - The company does not fall under the category of key pollutant discharge units as per environmental protection department regulations[101]. - The company has committed to avoiding any competition with its controlling shareholder, Su Enben, ensuring no conflicts of interest arise[120]. - The total number of ordinary shareholders as of the end of the reporting period is 31,625[128]. - The largest shareholder, Su Enben, holds 201,670,295 shares, accounting for 39.77% of the total shares[131].